Lucentis met late-stage trial goal in patients with macular edema due to BRVO

Image via Wikipedia

Genentech, Inc. announced that its macular degeneration drug Lucentis [ranibizumab] met its goal in a late stage trial, improving the vision of patients with macular edema due to branch retinal vein occlusion.

Currently, Lucentis is approved to treat neurovascular, or 'wet,' age-related macular degeneration. Genentech is now trying to get the drug approved for macular edema due to branch retinal vein occlusion, a condition in which the macula, or central part of the retina, swells because fluid leaks or builds up.

Posted in: Central retinal vein, Genentech, Macular Degeneration, Ranibizumab, Retina